The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. 1997

M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
Division of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam.

The major histocompatibility complex (MHC)-encoded transporter associated with antigen processing (TAP) translocates peptides from the cytosol into the lumen of the endoplasmic reticulum. This step precedes the binding of peptides to MHC class I molecules and is essential for cell surface expression of the MHC class I/peptide complex. TAP has a broad sequence specificity and a preference for peptides of around 9 amino acids. To synthesize inhibitors for TAP, we studied various alterations of the peptide substrate. The results indicate that TAP is stereospecific and that peptide bonds engineered into isosteric structures can improve translocation of the peptide. Furthermore, TAP is able to translocate peptides with large side chains that correspond to a peptide of approximately 21 amino acids in extended conformation. Peptides with longer side chains compete for the peptide binding site of TAP but fail to be translocated. Therefore, they represent the first rationally designed inhibitors of TAP.

UI MeSH Term Description Entries
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D000071181 ATP Binding Cassette Transporter, Subfamily B, Member 2 An ATP-binding cassette, sub-family B protein (ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B) that functions in the transport of ANTIGENS from the CYTOPLASM to the ENDOPLASMIC RETICULUM for association with HISTOCOMPATIBILITY ANTIGENS CLASS I peptides. It also acts as a molecular scaffold for the final stage of MHC class I PROTEIN FOLDING. ABCB2 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 2,ATP-Binding Cassette Sub-Family B Member 2,Antigen Peptide Transporter-1,Peptide Transporter PSF1,Peptide Transporter TAP1,RING4 Protein,Really Interesting New Gene 4 Protein,TAP-1 Protein,TAP1 Protein,Transporter 1, ATP-Binding Cassette, Sub-Family B (MDR-TAP),ATP Binding Cassette Sub Family B Member 2,Antigen Peptide Transporter 1,PSF1, Peptide Transporter,TAP 1 Protein,TAP1, Peptide Transporter
D000071450 ATP Binding Cassette Transporter, Subfamily B, Member 3 ATP-binding cassette, subfamily B, protein that functions in the transport of ANTIGENS from the CYTOPLASM to the ENDOPLASMIC RETICULUM for association with HISTOCOMPATIBILITY ANTIGENS CLASS I peptides. It functions as a heterodimer with ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 2. ABCB3 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 3,ATP-Binding Cassette, Sub-Family B, Member 3,Antigen Peptide Transporter-2,Peptide Supply Factor 2,Peptide Transporter Tap2,Antigen Peptide Transporter 2,Tap2, Peptide Transporter
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
June 2016, Journal of medicinal chemistry,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
October 2002, Mini reviews in medicinal chemistry,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
November 2020, Journal of medicinal chemistry,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
April 1990, Science (New York, N.Y.),
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
September 2019, Bioorganic & medicinal chemistry letters,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
May 2014, Chemical Society reviews,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
January 2003, Archives of biochemistry and biophysics,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
July 2012, ACS medicinal chemistry letters,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
January 2009, Advances in experimental medicine and biology,
M Grommé, and R van der Valk, and K Sliedregt, and L Vernie, and R Liskamp, and G Hämmerling, and J O Koopmann, and F Momburg, and J Neefjes
March 2014, ChemMedChem,
Copied contents to your clipboard!